Investor Presentation First Nine Months of 2022
16
Investor presentation
First nine months of 2022
Financial outlook for 2022
Sales growth - at CER
Expectations
2 November 2022
14% to 17%
Expectations
3 August 2022
12% to 16%
Sales growth - reported
Operating profit growth - at CER
Operating profit growth - reported
Around 10 percentage points higher
13% to 16%
Around 15 percentage points higher
Around 9 percentage points higher
11% to 15%
Around 14 percentage points higher
Financial items (net)
Effective tax rate
Free cash flow
Note: Changes since last highlighted in bold
Loss of around DKK 6.6 billion
20% to 22%
DKK 54 to 59 billion
Loss of around DKK 5.5 billion
20% to 22%
DKK 57 to 62 billion
Novo NordiskⓇ
The financial outlook is based on an assumption of a continuation of the current business environment and given the current scope of business activities and has been prepared assuming that currency exchange rates remain at the level as of 26 October 2022View entire presentation